The parameters associated with the intervention included: the background mortality and mortality for the first year after hip fracture; the age-adjusted probability and risk functions of each type of fracture; the odds ratio of a radiographic vertebral fracture; the incidence rate of radiographic vertebral fracture; a gradual linear loss of fracture reduction benefit with alendronate; the prevalence of osteoporosis at the femoral neck; the proportions of those with and without prior clinical fracture who had osteoporosis at each age; and NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination permanent long-term care.
Modelling
A computer simulation state transition Markov model was constructed to follow the course of events. The model considered multiple clinical fractures. The health states were well reported and a number of modelling assumptions were fully justified. Individuals were at risk of transition to a different state once every 3 months and were followed up until death or age 105 years. For the base-case analyses, the model was run for sub-sets of elderly men with or without a prior clinical fracture at five different starting ages (65, 70, 75, 80 and 85 years) using Monte Carlo simulations. For each simulation, 50,000 men were put through each of the two strategies of the model, one at a time.
Sources searched to identify primary studies
Data were taken from:
2003 US vital statistics and national health survey (NHANES); several US and foreign observational studies; published and unpublished data from a large observational study, Osteoporotic Fractures in Men (MrOS) study (Cummings et al. 2006 and Orwoll et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details); a meta-analysis of published prospective, randomised clinical trials of alendronate in men (Sawka et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details); and a meta-analysis of hip fracture (Johnell et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details).
Methods used to judge relevance and validity, and for extracting data
The process used to identify the data was not reported. No inclusion criteria were specified for any of the parameters. The method used to select the estimates was neither reported nor discussed.
Measure of benefits used in the economic analysis
The authors used quality-adjusted life-years (QALY) as a measure of benefit. The utility data were derived from population-based surveys for the no-fracture state for elderly men (QALY value of 0.7). Fracture disutility was modelled as a lower value of a QALY compared with the no-fracture state. The disutilities for the first year following fractures were derived from Swedish prospective studies of elderly men and women (Borgstrom et al. 2006 and Kanis et al. 2004 , see 'Other Publications of Related Interest' below for bibliographic details). Secondary analyses were performed, assuming a QALY value of 1.0, to compare estimated life-years saved with the densitometry and treatment (DT) strategy versus NI. The benefits were discounted at an annual rate of 3%.
Direct costs
The cost categories included in the model were:
the cost of oral bisphosphonates and annual physician visits; the cost of a bone density test and one additional test after 2 years' drug therapy; the costs of acute hip, clinical vertebral, distal forearm and other fractures; the long-term care cost for the first year after hip fracture and the cost per day of long-term care; and
